Biomea Fusion, Inc. (BMEA)

Market Cap	590.49M
Revenue (ttm)	n/a
Net Income (ttm)	-107.69M
Shares Out	35.40M
EPS (ttm)	-3.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,153
Open	15.51
Previous Close	15.07
Day's Range	14.09 - 17.18
52-Week Range	6.04 - 43.69
Beta	-0.97
Analysts	Strong Buy
Price Target	47.70 (+185.97%)
Earnings Date	Oct 30, 2023

About BMEA

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 16, 2021
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: BMEA

Analyst Forecast

According to 10 analysts, the average rating for BMEA stock is "Strong Buy." The 12-month stock price forecast is $47.7, which is an increase of 185.97% from the latest price.

Price Target

$47.7

(185.97% upside)

Analyst Consensus: Strong Buy